Genenta Science S.p.A. (GNTA)
NasdaqCM: GNTA
· Real-Time Price · USD
1.30
+0.00 (0.00%)
At close: Aug 11, 2026, 3:59 PM
Genenta Science S.p.A. (GNTA) Stock Price, Analysis & Data
0.00% (1D)
| Bid | 1.53 |
| Market Cap | 62.68M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -6.53M |
| Beta | 0.77 |
| EPS (ttm) | -0.38 |
| PE Ratio (ttm) | n/a |
| Forward PE | -2 |
| P/B (ttm) | 1.21 |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | 2.67 |
| Volume | 30,392 |
| Avg. Volume (20D) | 1,482,441 |
| Open | 1.31 |
| Previous Close | 1.30 |
| Day's Range | 1.30 - 1.37 |
| 52-Week Range | 0.55 - 10.00 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About GNTA
Genenta Science S.p.A., a clinical-stage biotechnology company, develops hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company offers Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is developing Temferon for use in the treatment of other solid tumor indications. In addition, the company develops biolo...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 15, 2021
Employees 9
Stock Exchange NasdaqCM
Ticker Symbol GNTA
Website https://www.genenta.com
Financial Performance
In 2025, Genenta Science S.p.A.'s revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -6.53M, a decrease of -26.73%.
Financial Statements
Page 1 of 2